Innovative Heart Health Diagnostics: An Interview with Chase Spoor of FluoroPharma 00:10:00

Share On Facebook Share On Twitter

Mr. Spoor was previously President and CEO of AzurRx since its founding in June 2014. At AzurRx, he successfully led the Company through its Phase 2 study of MS1819-SD in chronic pancreatitis and its Phase 2 OPTION study of MS1819 in cystic fibrosis. He was previously President, Chief Executive Officer and a member of the Board of Directors of Fluoropharma Medical, Inc., was the CFO for Sunstone BioSciences, a nanotechnology firm, and a strategy consultant at Oliver Wyman working with biotechnology, pharmaceutical, medical device and health insurance companies.

Recent Videos